Electroconvulsive therapy modulates plasma pigment epithelium-derived factor in depression: a proteomics study

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• Electroconvulsive therapy (ECT) is a highly effective treatment for severe depression.
• The precise molecular mechanisms underlying ECT's efficacy remain largely unknown.
• Peripheral blood proteomic analysis offers a potential avenue to explore ECT's biological underpinnings.

Purpose of the Study:

• To investigate the peripheral blood proteomic changes associated with electroconvulsive therapy (ECT) in patients with major depressive disorder.
• To identify specific proteins altered by ECT and validate their role in the therapeutic response.
• To explore the expression of identified proteins in an animal model of ECT.

Main Methods:

• Discovery phase: Plasma proteomic analysis using 2D-DIGE and mass spectrometry in patients pre-/post-ECT (n=30).
• Confirmation phase: Immunodetection assays for identified proteins in a separate patient cohort (n=57) and healthy controls (n=43).
• Animal model: Assessment of target protein mRNA levels in rat brain and blood following electroconvulsive stimulation (ECS).

Main Results:

• ECT significantly altered 121 protein spots, with 36 proteins identified by mass spectrometry.
• A significant post-ECT increase in plasma pigment epithelium-derived factor (PEDF) was confirmed.
• Elevated plasma PEDF levels were observed in depressed patients compared to controls, further increasing post-ECT. Chronic ECS increased PEDF mRNA in rat hippocampus and dentate gyrus.

Conclusions:

• This study identifies alterations in peripheral blood pigment epithelium-derived factor (PEDF) levels in patients with depression and following electroconvulsive therapy (ECT).
• Findings suggest a potential role for PEDF in the biological response to ECT for depression.
• The results implicate PEDF as a mediator in the neurobiological effects of ECT.